SUMMARY A reappraisal of survival data on patients with uveal melanomas has led us to these impressions: (a) that the mortality rate before enucleation is low, estimated at 1 % per year; (b) that the mortality rate rises abruptly following enucleation, reaching a peak of about 8 % during the second year after enucleation; and (c) that approximately two-thirds of the fatalities could be attributed to the dissemination of tumour emboli at the time of enucleation. From these impressions we believe the following conclusions are warranted: (a) enucleation as it has been performed in the past may have for many patients an adverse rather than a beneficial effect with respect to the development of metastatic disease from malignant melanoma of the choroid and ciliary body. (b) A long-term follow-up study of untreated patients with melanomas of the choroid and ciliary body is indicated. (c) New techniques for enucleation designed to prevent the dissemination of tumour cells must be developed and tested to enable the ophthalmic surgeon to remove safely the tumour-containing eye that has developed such complications as uncontrollable glaucoma, panophthalmitis, or proptosis from extraocular extension.
Recently in reviewing lantern slides while preparing for a lecture on uveal melanomas, the senior author observed for the first time that the old, previously published graph shown in Fig. 1 (Paul et al., 1962; Zimmerman, 1967) , illustrating the prognostic significance of cell type, seemed to contain hidden information that had heretofore escaped recognition. We interpreted and spoke as if time zero were the beginning of an experiment. If these curves represented survival of animals after the introduction of different types of melanoma cells at time zero, then all would be clear. What has often failed to be recognised in evaluating such survival curves is that there is no way of knowing when the biological experiment began, how many additional cases were diagnosed but not treated by enucleation, or how many undiagnosed cases there may have been, including those that may have proved fatal. As a matter of fact it would seem quite certain that the time of onset is an extremely variable factor, often antedating by years the time of discovery and enucleation. To appreciate the hidden significance of the data presented in Fig. 1 fully, one must consider the following background information.
First, it is generally believed and widely taught that uveal melanomas, unlike cutaneous melanomas and unlike many other malignant tumours, are rarely observed to have metastasised before the patient is referred for treatment of the primary tumour (Hogan, 1964; Duke-Elder and Perkins, 1966) . The pre-enucleation clinical and radiological evaluations also seldom turn up any evidence of metastatic disease (Jensen, 1963) (Koenig, 1954; Anderson and O'Neill, 1957; Char and Hogan, 1977; Curtin, 1977; Dunphy, 1977; Gass, 1977; Hagler et al., 1977 Parsons, 1905; Zimmerman and Adler, 1957; Duke-Elder and Perkins, 1966; Raivio, 1977; Ruiz, 1977) . Raivio (1977) , who recently reported on a comprehensive analysis based on 378 uveal melanoma cases in Finland, found that there were 32 patients whose tumour-containing eyes had been observed for some time prior to enucleation. Although evidence of growth had been found in each instance, no spread had been observed, and the survival rates after enucleation for these patients were no different from those of other patients whose eyes had been enucleated promptly after discovery of the tumours. In addition, there were 5 patients who had refused enucleation. One died of unrelated causes after 1 year. The other 4 patients eventually died of metastatic disease, but of great interest is the fact that in none of these cases did the tumour prove lethal in less than 2 years, the deaths having occurred after 2, 3, 14, and 15 years.
Our follow-up data ( Fig. 1 ) and those of other investigators (Benjamin et al., 1948; Chisholm, 1953; Westerveld-Brandon and Zeeman, 1957; Jensen, 1963) show that there is a significant mortality that becomes evident after enucleation. (Fig. 2) . The solid line (curve E-P) in Fig. 2 represents survival after enucleation of the 2652 patients in the study of Paul and co-workers (1962 (1962) . It is also evident that for the first 11 years the hypothetical survival of untreated patients represented in curve E-C is also better than that of the treated patients in curve E-P. From the data of Paul et al. (1962) used to construct the survival curve E-P we have calculated the changing annual mortality rate following enucleation to construct the graph shown in Fig. 3 . This reveals more dramatically the rapid rise in mortality that follows enucleation, reaching a peak during the second postenucleation year. Then during the ensuing several years the tumour death rate falls, reaching a low, apparently constant level about 6 to 7 years after enucleation. After having made these observations we discovered that Benjamin and co-workers (1948) in the follow-up study of a large series of British cases published a graph revealing a remarkably similar pattern. In a discussion of metastatic disease from uveal melanomas Jensen (1963) presented a graph which again reflects this striking pattern of a rapidly rising incidence after enucleation and reaching a peak 2 to 3 years after enucleation. Fraunfelder and co-workers (1977) have for several years suspected that this might be the case and they have designed experiments to test the hypothesis (Burns et al., 1962; Fraunfelder and Boozman, 1974) . They showed that, while a quick atraumatic method of enucleation of the hamster eye tended to prevent dissemination of tumour cells, the conventional surgical technique was less effective. However, neither method of enucleation was curative except in a few animals. More recently they have shown that the conventional techniques for enucleation are accompanied by great fluctuations in intraocular pressure, which could, along with the traumatic effects of direct handling of the tissues, be responsible for a considerable increase in intravasation of tumour cells (Fraunfelder et al., 1977) . Such a release of melanoma cells into the circulation during enucleation might well overwhelm whatever beneficial immunological defence mechanisms the patient may have mobilised prior to enucleation.
From these assumptions we have formulated a mathematical model to describe the mortality rate observed with uveal melanomas treated by enucleation. Features and assumptions incorporated into the model are:
(1) The death rate is equal to the metastatic rate, i.e., the rate at which tumour emboli become established as metastatic foci and start growing in distant sites. But obviously there is a lag period between time of metastasis and the time of death, as it takes time for established metastatic foci to grow and kill the patient.
(2) The shower of emboli released at enucleation causes the rate of metastasis to increase exponentially up to a maximum level.
(3) Counteracting the shower of emboli and the metastatic foci are host defences which attempt to destroy the released tumour cells at an exponential rate.
(4) There is a constant mortality rate that is independent of enucleation. The model is: (Flocks et al., 1955; McLean et al., 1977) . All such studies have also been retrospective and based entirely on cases treated by enucleation. Thus the basic principles would still apply, but the adverse effects of enucleation would be greater if one restricted the analysis to large tumours or to tumours containing epithelioid cells. On the other hand one would encounter the least chance of disseminating tumour cells if one selected only small spindle cell tumours for enucleation. This provides another explanation for the excellent follow-up results obtained in the treatment of melanomas of the iris (Ashton, 1964; Zimmerman, 1971-72) .
The suggestion of Fraunfelder et al. (1977) that we need some sort of 'no-touch technique' for enucleation must be heeded. A first step, however, is to develop a new philosophy regarding all sorts of manipulation of the eye containing a melanoma. This would include curtailment of repeated examinations by the entire resident staff and miscellaneous visiting ophthalmologists who might want to use such aids as vigorous scleral depression and transillumination during their examinations. It would also require a change in the policy of many teaching institutions that assign to first-year residents, who have the least surgical expertise, the responsibility for performing enucleations.
Many recent articles have indicated that because of the lack of controlled studies we do not have proof of the benefits derived from enucleation in the treatment of uveal melanomas, but only rarely has it been suggested that the surgeon may actually hasten the dissemination of tumour while performing an enucleation (Westerveld-Brandon and Zeeman, 1957; Zimmerman and McLean, 1975; Fraunfelder et al., 1977) . According to the Hippocratic doctrine physicians should at least do no harm (Blomquist, 1977) . It is time we tried to learn exactly what we are doing for (or against) the patient when we recommend enucleation for uveal melanomas.
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